TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Rhea-AI Summary
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immuno-oncology company, announced that President and CEO James A. Bianco, M.D. will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City.
The session is scheduled for Tuesday, May 19, 2026 at 2:00 pm ET, with live and archived webcasts available on TuHURA's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – HURA
In the May 12 session, HURA gained 0.83%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Credit facility funding | Positive | +4.1% | Announced $50M credit facility extending cash runway into 2028. |
| Apr 07 | Management appointment | Positive | +1.7% | Appointed SVP of Clinical Operations with 20+ years development experience. |
| Apr 01 | Earnings and update | Negative | -9.5% | Reported 2025 results with $3.6M cash and higher R&D-driven losses. |
| Mar 23 | Clinical leadership move | Positive | +2.1% | Former JNJ oncology head to lead TBS‑2025 blood cancer program. |
| Feb 27 | Nasdaq compliance | Positive | +3.1% | Regained compliance with Nasdaq $1.00 minimum bid price requirement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, whether financial, operational, or clinical, has consistently seen price moves in the same direction as the apparent news tone, with no recorded divergences in the last five events.
Over the last few months, TuHURA has highlighted multiple de-risking and growth steps. A $50 million credit facility extended its anticipated cash runway into 2028, while leadership hires strengthened clinical and development execution. Financial updates showed higher R&D and net losses, alongside capital raises and the Kineta acquisition. The company also regained Nasdaq minimum bid price compliance and advanced its Phase 3 IFx‑2.0 program and TBS‑2025 plans. Today’s conference participation fits into this pattern of active investor and clinical communication.
Key Terms
immuno-oncology medical
cancer immunotherapy medical
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
4th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click HERE.
A live and archived webcast of the presentation will also be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, a VISTA inhibiting mAb moving into Phase 1b/2 in mutNPM1 r/r AML, a molecularly defined subgroup of patients with AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html
SOURCE TuHURA Biosciences, Inc.